Loading...

APC anti-human CD19 Antibody

Pricing & Availability
Clone
HIB19 (See other available formats)
Regulatory Status
RUO
Workshop
V CD19.11
Other Names
B4
Isotype
Mouse IgG1, κ
Ave. Rating
Submit a Review
Product Citations
publications
HIB19_APC_061807
Human peripheral blood lymphocytes stained with HIB19 APC
  • HIB19_APC_061807
    Human peripheral blood lymphocytes stained with HIB19 APC
Compare all formats See APC spectral data
Cat # Size Price Quantity Check Availability Save
302211 25 tests 44 CHF
Check Availability


Need larger quantities of this item?
Request Bulk Quote
302212 100 tests 105 CHF
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD19 is a 95 kD type I transmembrane glycoprotein also known as B4. It is a member of the immunoglobulin superfamily expressed on B-cells (from pro-B to blastoid B cells, absent on plasma cells) and follicular dendritic cells. CD19 is involved in B cell development, activation, and differentiation. CD19 forms a complex with CD21 (CR2) and CD81 (TAPA-1), and functions as a BCR co-receptor.

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
Human
Reported Reactivity
Chimpanzee
Antibody Type
Monoclonal
Host Species
Mouse
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA)
Preparation
The antibody was purified by affinity chromatography, and conjugated with APC under optimal conditions.
Concentration
Lot-specific (to obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool.)
Storage & Handling
The CD19 antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is 5 µl per million cells in 100 µl staining volume or 5 µl per 100 µl of whole blood.

Excitation Laser
Red Laser (633 nm)
Application Notes

Additional reported applications (for the relevant formats) include: immunohistochemical staining of acetone-fixed frozen tissue sections8 and blocking of B cell proliferation. Clone HIB19 is not recommended for formalin-fixed paraffin-embedded sections. The Ultra-LEAF™ purified antibody (Endotoxin < 0.01 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. No. 302267 & 302268).

 

Clone HIB19 partially blocks anti-human CD19 clones 4G7 and SJ25C1 staining based on in-house testing

Additional Product Notes

View more applications data for this product in our Scientific Poster Library.

Application References

(PubMed link indicates BioLegend citation)
  1. Schlossman S, et al. 1995. Leucocyte Typing V. Oxford University Press. New York.
  2. Knapp W, et al. 1989. Leucocyte Typing IV. Oxford University Press. New York.
  3. Bradbury L, et al. 1993. J. Immunol. 151:2915.
  4. Joseph A, et al. 2010. J. Virol. 84:6645. PubMed
  5. Wang X, et al. 2010. Haematologica. 95:884. (FC) PubMed
  6. Walker JD, et al. 2009. J. Immunol. 182:1548. (Block) PubMed
  7. Yoshino N, et al. 2000. Exp. Anim. (Tokyo) 49:97. (FC)
  8. Hansen A, et al. 2002. Arthritis Rheum. 46:2160. (IHC)
  9. Stoeckius M, et al. 2017. Nat. Methods. 14:865. (PG)
  10. Peterson VM, et al. 2017. Nat. Biotechnol. 35:936. (PG)
Product Citations
  1. He T, et al. 2022. Liver Int. 42:1287. PubMed
  2. Li Y, et al. 2022. J Med Virol. 94:3998. PubMed
  3. Qin K, et al. 2022. Nat Genet. 54:874. PubMed
  4. Sulaj A, et al. 2022. J Clin Endocrinol Metab. 107:2167. PubMed
  5. Simpson AP, et al. 2022. Cell Rep. 40:111099. PubMed
  6. Wheeler MM, et al. 2022. Nat Commun. 13:7592. PubMed
  7. Touizer E, et al. 2023. iScience. 26:105862. PubMed
  8. Guo Q, et al. 2023. Front Public Health. 10:1067342. PubMed
  9. Liao J, et al. 2023. Nat Commun. 14:207. PubMed
  10. Wang P, et al. 2023. Front Immunol. 13:1104329. PubMed
  11. Pariury H, et al. 2023. Haematologica. :. PubMed
  12. He T, et al. 2023. Immun Inflamm Dis. 11:e759. PubMed
  13. Zhang S, et al. 2023. J Clin Med. 12: . PubMed
  14. Liu X, et al. 2022. J Virol. 96:e0025722. PubMed
  15. Zhu I, et al. 2022. Cell. 185:1431. PubMed
  16. Castañeda-Partida L, et al. 2022. Discov Oncol. 13:28. PubMed
  17. Chabi S, et al. 2020. Cell Reports. 29(8):2307-2320.e6.. PubMed
  18. Bhattacharya S, et al. 2020. Front Bioeng Biotechnol. 1.055555556. PubMed
  19. Chen HY, et al. 2022. Elife. 11:. PubMed
  20. Witkowski MT, et al. 2022. Nat Immunol. 23:1424. PubMed
  21. Varun K, et al. 2023. EBioMedicine. 90:104516. PubMed
  22. Hu X, et al. 2023. Nat Commun. 14:2020. PubMed
  23. Wali G, et al. 2023. Front Neurosci. 17:1073516. PubMed
  24. Toriyama M, et al. 2023. Front Mol Biosci. 10:1149828. PubMed
  25. Lu T, et al. 2023. J Med Virol. 95:e28730. PubMed
  26. Li H, et al. 2022. Front Immunol. 13:988004. PubMed
  27. Keim D, et al. 2021. Int J Mol Sci. 22:. PubMed
  28. Nakano M, et al. 2021. Front Immunol. 12:713225. PubMed
  29. Guo X, et al. 2016. Mol Ther Methods Clin Dev. 3:15054. PubMed
  30. Rendeiro AF, et al. 2020. Nat Commun. 11:577. PubMed
  31. Ivan Jelcic et al. 2018. Cell. 175(1):85-100 . PubMed
  32. Vinjamur DS, et al. 2021. Nat Genet. 53:719. PubMed
  33. Richardson SE, et al. 2021. STAR Protocols. 2(2):100420. PubMed
  34. Rochat MA, et al. 2018. Virol J. 15:191. PubMed
  35. Yarzabek B et al. 2018. eLife. 7 pii: e34961. PubMed
  36. Turner JS, et al. 2021. Nature. 596:109. PubMed
  37. Mitsune A, et al. 2021. Respir Res. 22:232. PubMed
  38. Li T, et al. 2022. Int J Infect Dis. 122:874. PubMed
  39. Weisberg SP, et al. 2020. Cell Reports. 29(12):3916-3932.e5.. PubMed
  40. Zhong J, et al. 2018. Sci Adv. 4:eaas9864. PubMed
  41. Alenazy MF, et al. 2021. Sci Rep. 11:5629. PubMed
  42. Kang L, et al. 2020. Exp Hematol Oncol. 9:11. PubMed
  43. Veras FP, et al. 2020. J Exp Med. 217:00:00. PubMed
  44. Shi Z, et al. 2019. Cell Discov. 0.252777778. PubMed
  45. Alsaleh G, et al. 2020. Elife. 9: . PubMed
  46. Dai Q, et al. 2020. Front Immunol. 11:539654. PubMed
  47. Wu Y, et al. 2019. Nat Med. 25:776. PubMed
  48. Riboldi E, et al. 2011. J Biol Chem. 286:35329. PubMed
  49. Yin W, et al. 2021. Thorac Cancer. 12:2680. PubMed
  50. Constantinescu-Bercu A, et al. 2020. eLife. 9:00. PubMed
  51. Ramos RN, et al. 2022. Clin Transl Immunology. 11:e1392. PubMed
  52. Lan X, et al. 2020. Molecular Cell. 81(2):239-254.e8. PubMed
  53. Witkowski MT, et al. 2020. Cancer Cell. 37:867. PubMed
  54. Urlaub D, et al. 2019. Arthritis Res Ther. 1.067361111. PubMed
  55. Velázquez–Avila M, et al. 2019. Leukemia. 33:1337. PubMed
  56. Alhaj Hussen K, et al. 2017. Immunity. 47:680. PubMed
  57. Caeser R, et al. 2021. Nat Protoc. 16:2499. PubMed
  58. Yang L, et al. 2020. Genes Dis. 7:128. PubMed
  59. Guan J, et al. 2018. Mol Cancer Ther. 17:1090. PubMed
  60. Zhang H, et al. 2019. Mol Cell. 76:110. PubMed
  61. Vabret N, et al. 2022. iScience. 25:104599. PubMed
  62. Lee M, et al. 2020. Elife. :9. PubMed
  63. Zeng J, et al. 2020. Nat Med. 26:535. PubMed
  64. Mohiuddin M, et al. 2016. Nat Commun. 7: 11138. PubMed
  65. Messinger JE, et al. 2019. MBio. 10. PubMed
  66. Nelde A, et al. 2018. Oncoimmunology. 7:e1316438. PubMed
  67. den Hartog G, et al. 2018. Eur J Immunol. 48:283. PubMed
  68. Song R, et al. 2022. Front Immunol. 13:1028246. PubMed
  69. Lee HJ, et al. 2017. Oncotarget. 8:113345. PubMed
  70. Paul S, et al. 2021. Sci Transl Med. 13:. PubMed
  71. Linedale R, et al. 2017. PLoS One. 12:e0175755. PubMed
  72. Roybal KT et al. 2016. Cell. 167(2):419-432 . PubMed
  73. Benci JL et al. 2019. Cell. 178(4):933-948 . PubMed
  74. Nakachi S, et al. 2017. Arthritis Research & Therapy . 10.1186/s13075-017-1309-x. PubMed
  75. Audigé A, et al. 2017. BMC Immunology. 10.1186/s12865-017-0209-9. PubMed
  76. O'Donoghue GP, et al. 2021. Proc Natl Acad Sci U S A. 118:. PubMed
  77. Isobe T, et al. 2022. Nat Commun. 13:4501. PubMed
  78. Aagaard K, et al. 2017. Sci Rep. 7:41389. PubMed
  79. Zhao NQ, et al. 2020. PLoS One. 15:e0238347. PubMed
  80. Molina MS, et al. 2021. Front Immunol. 12:699128. PubMed
  81. Reyes M, et al. 2021. Sci Transl Med. 13:. PubMed
  82. Luvanda MK, et al. 2021. J Fungi (Basel). 7:. PubMed
  83. S Tzeng 2016. J Vis Exp. 118:e54582. PubMed
  84. Xu L, et al. 2019. Haematologica. 10.3324/haematol.2018.207258. PubMed
  85. Gärtner K, et al. 2019. J Extracell Vesicles. 8:1573051. PubMed
  86. Lavaert M, et al. 2020. Immunity. 52(6):1088-1104. PubMed
  87. Bouvet M, et al. 2021. MBio. 12: . PubMed
  88. Gao P, et al. 2021. Nat Commun. 1194:12. PubMed
  89. Moreno I, et al. 2010. PLoS One. 5:e743. PubMed
  90. Alhaj Hussen K, et al. 2020. Front Immunol. 11:579776. PubMed
  91. Evers M, et al. 2020. MAbs. 12:1795505. PubMed
  92. Yamaguchi K, et al. 2018. Cancer Sci. 109:3032. PubMed
RRID
AB_314241 (BioLegend Cat. No. 302211)
AB_314242 (BioLegend Cat. No. 302212)

Antigen Details

Structure
Ig superfamily, type I transmembrane glycoprotein, 95 kD
Distribution

B lineage (except plasma cells), follicular dendritic cells

Function
B cell activation and differentiation
Ligand/Receptor
Forms complex with CD21 (CR2) and CD81 (TAPA-1), BCR coreceptor
Cell Type
B cells, Dendritic cells
Biology Area
Costimulatory Molecules, Immunology
Molecular Family
CD Molecules
Antigen References

1. Tedder T, et al. 1994. Immunol. Today 15:437.
2. Bradbury L, et al. 1993. J. Immunol. 151:2915.

Gene ID
930 View all products for this Gene ID
Specificity (DOES NOT SHOW ON TDS):
CD19
Specificity Alt (DOES NOT SHOW ON TDS):
CD19
App Abbreviation (DOES NOT SHOW ON TDS):
FC
UniProt
View information about CD19 on UniProt.org

Related FAQs

There are no FAQs for this product.

Other Formats

View All CD19 Reagents Request Custom Conjugation
Description Clone Applications
APC anti-human CD19 HIB19 FC
Biotin anti-human CD19 HIB19 FC
FITC anti-human CD19 HIB19 FC
PE anti-human CD19 HIB19 FC
PE/Cyanine5 anti-human CD19 HIB19 FC
Purified anti-human CD19 HIB19 FC,CyTOF®,IHC-F
APC/Cyanine7 anti-human CD19 HIB19 FC
PE/Cyanine7 anti-human CD19 HIB19 FC
Alexa Fluor® 488 anti-human CD19 HIB19 FC,ICC
Alexa Fluor® 647 anti-human CD19 HIB19 FC,IHC-F
Pacific Blue™ anti-human CD19 HIB19 FC
Alexa Fluor® 700 anti-human CD19 HIB19 FC
PerCP anti-human CD19 HIB19 FC
PerCP/Cyanine5.5 anti-human CD19 HIB19 FC
Brilliant Violet 421™ anti-human CD19 HIB19 FC,ICC,IHC-F
Brilliant Violet 570™ anti-human CD19 HIB19 FC
Brilliant Violet 650™ anti-human CD19 HIB19 FC
Brilliant Violet 785™ anti-human CD19 HIB19 FC
Brilliant Violet 510™ anti-human CD19 HIB19 FC
Brilliant Violet 605™ anti-human CD19 HIB19 FC
Brilliant Violet 711™ anti-human CD19 HIB19 FC
Purified anti-human CD19 (Maxpar® Ready) HIB19 FC,CyTOF®
Alexa Fluor® 594 anti-human CD19 HIB19 ICC,IHC-F
PE/Dazzle™ 594 anti-human CD19 HIB19 FC
PE anti-human CD19 HIB19 FC
APC/Fire™ 750 anti-human CD19 HIB19 FC
Pacific Blue™ anti-human CD19 HIB19 FC
APC anti-human CD19 HIB19 FC
PE/Cyanine7 anti-human CD19 HIB19 FC
TotalSeq™-A0050 anti-human CD19 HIB19 PG
Brilliant Violet 750™ anti-human CD19 HIB19 FC
TotalSeq™-B0050 anti-human CD19 HIB19 PG
TotalSeq™-C0050 anti-human CD19 HIB19 PG
PerCP/Cyanine5.5 anti-human CD19 HIB19 FC
Spark NIR™ 685 anti-human CD19 HIB19 FC
Ultra-LEAF™ Purified anti-human CD19 HIB19 FC,CyTOF®,Block,IHC
APC/Fire™ 810 anti-human CD19 HIB19 FC
PE/Fire™ 640 anti-human CD19 HIB19 FC
PE/Fire™ 700 anti-human CD19 HIB19 FC
TotalSeq™-D0050 anti-human CD19 HIB19 PG
Spark YG™ 593 anti-human CD19 HIB19 FC
GMP Pacific Blue™ anti-human CD19 HIB19 FC
Spark Violet™ 423 anti-human CD19 HIB19 FC
GMP PE anti-human CD19 HIB19 FC
GMP APC anti-human CD19 HIB19 FC
KIRAVIA Blue 520™ anti-human CD19 HIB19 FC
GMP PerCP/Cyanine5.5 anti-human CD19 HIB19 FC
GMP PE/Cyanine7 anti-human CD19 HIB19 FC
Spark Violet™ 500 anti-human CD19 HIB19 FC
PE/Fire™ 810 anti-human CD19 HIB19 FC
Spark Violet™ 423 anti-human CD19 HIB19 FC
Spark UV™ 387 anti-human CD19 HIB19 FC
APC/Fire™ 750 anti-human CD19 HIB19 FC
PE/Cyanine5 anti-human CD19 HIB19 FC
Alexa Fluor® 660 anti-human CD19 HIB19 FC
PerCP/Fire™ 806 anti-human CD19 HIB19 FC
PerCP/Fire™ 780 anti-human CD19 HIB19 FC
Spark PLUS UV™ 395 anti-human CD19 HIB19 FC
Spark Red™ 718 anti-human CD19 HIB19 FC
Go To Top Version: 2    Revision Date: 12.18.2013

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account